Intravitreal Anti-VEGF Therapy in Advanced CKD
Intravitreal anti-VEGF therapy can be safely administered to this gentleman with eGFR 27 mL/min, but consider switching to aflibercept or dexamethasone implant if bevacizumab shows poor response after 3 monthly injections, and monitor renal function closely during treatment.
Treatment Algorithm
Initial Therapy Selection
Anti-VEGF agents remain the preferred first-line therapy for retinal conditions requiring intravitreal treatment, even in patients with advanced chronic kidney disease (CKD stage 4, eGFR 15-29 mL/min) 1. The evidence demonstrates:
- Bevacizumab can be initiated as first-line therapy (off-label, cost-effective)
- Ranibizumab (FDA-approved) and aflibercept (FDA-approved) are equally appropriate initial choices
- All three agents have demonstrated efficacy in major clinical trials (BRAVO, CRUISE, VIBRANT, COPERNICUS, GALILEO) 1, 2, 1, 2
Critical Consideration for Reduced Renal Function
The key clinical caveat: A 2022 study specifically examining treatment response by renal function found that bevacizumab shows significantly reduced efficacy in patients with eGFR <30 mL/min 3. After three consecutive monthly bevacizumab injections:
- Patients with preserved renal function (eGFR ≥60): significant improvement in visual acuity and central subfield thickness (p<0.001)
- Patients with severe CKD (eGFR <30): no significant improvement in either parameter
- Switching to aflibercept or dexamethasone implant produced significantly better results in the poor responders with decreased renal function 3
Recommended Treatment Protocol
For this patient with eGFR 27 mL/min:
- Start with 3 monthly injections of bevacizumab (most cost-effective), ranibizumab, or aflibercept
- Assess response at 3 months - evaluate both visual acuity and anatomical response (OCT)
- If poor response after 3 injections: Switch to aflibercept (if started on bevacizumab) or dexamethasone implant 3
- If good response: Continue with treat-and-extend or PRN protocol based on clinical findings
Alternative First-Line Option
Given the eGFR of 27 mL/min, consider starting directly with aflibercept rather than bevacizumab, as:
- Higher eGFR correlates with better anatomical response to anti-VEGF therapy 4
- Aflibercept may provide superior outcomes in patients with compromised renal function 3
- This avoids the 3-month trial period with potentially ineffective bevacizumab
Renal Function Monitoring
Essential monitoring protocol for this patient:
- Baseline eGFR is a critical predictor - patients with eGFR 15-30 mL/min show the greatest decline in renal function during anti-VEGF treatment (mean -37.4% at 24 months) 5
- Monitor eGFR every 3-6 months during active treatment 6, 5
- Risk of dialysis: 1.9% with ranibizumab vs 8.9% with aflibercept in one study, though not statistically significant 5
- Patients with baseline eGFR ≤30 mL/min who receive intravitreal anti-VEGF show significantly decreased renal function compared to untreated controls 6
However, contradictory evidence exists: A 2023 study found that visual and anatomical improvements with anti-VEGF therapy were independent of baseline GFR, suggesting low GFR should not dictate injection timing 7. Another 2023 study found intravitreal anti-VEGF was associated with increased risk of kidney decline only in patients with eGFR >30 mL/min, not ≤30 mL/min 8.
Corticosteroid Alternative
Intravitreal dexamethasone implant is a viable alternative if anti-VEGF fails or is contraindicated 2, 1:
- FDA-approved for retinal vein occlusions
- May be particularly effective in patients with poor anti-VEGF response and renal dysfunction 3
- Major risks: cataract formation and elevated IOP (monitor closely)
- Consider especially if patient is pseudophakic
Injection Safety Protocol
Standard precautions apply regardless of renal function:
- Use topical povidone-iodine before all injections (mandatory) 1, 9
- Do NOT use routine antibiotic drops - not recommended and does not reduce endophthalmitis risk 1, 9
- Severe complications remain rare: endophthalmitis (0.019-0.09%), retinal detachment, cataract, elevated IOP 9
Systemic Safety Considerations
- Meta-analyses show no evidence of increased arterial thromboembolic events with anti-VEGF therapy 1
- Moderate certainty evidence supports overall safety of anti-VEGF injections 9
- The favorable risk-to-benefit profile supports anti-VEGF as preferred initial therapy even in advanced CKD 1
Clinical Pitfalls to Avoid
- Do not withhold anti-VEGF therapy solely based on low eGFR - the ocular benefits typically outweigh renal risks
- Do not continue bevacizumab indefinitely if no response after 3 months in severe CKD - switch agents 3
- Do not ignore declining renal function - patients with eGFR 15-30 mL/min are at highest risk for further decline 5
- Do not assume all anti-VEGF agents perform equally in advanced CKD - evidence suggests differential responses 3